150 related articles for article (PubMed ID: 9138662)
1. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis.
Kantoff PW; Febbo PG; Giovannucci E; Krithivas K; Dahl DM; Chang G; Hennekens CH; Brown M; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):189-92. PubMed ID: 9138662
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
[TBL] [Abstract][Full Text] [Related]
4. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
Allen NE; Reichardt JK; Nguyen H; Key TJ
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
[TBL] [Abstract][Full Text] [Related]
5. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.
Makridakis N; Ross RK; Pike MC; Chang L; Stanczyk FZ; Kolonel LN; Shi CY; Yu MC; Henderson BE; Reichardt JK
Cancer Res; 1997 Mar; 57(6):1020-2. PubMed ID: 9067262
[TBL] [Abstract][Full Text] [Related]
6. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.
Reichardt JK; Makridakis N; Henderson BE; Yu MC; Pike MC; Ross RK
Cancer Res; 1995 Sep; 55(18):3973-5. PubMed ID: 7664265
[TBL] [Abstract][Full Text] [Related]
7. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.
Febbo PG; Kantoff PW; Platz EA; Casey D; Batter S; Giovannucci E; Hennekens CH; Stampfer MJ
Cancer Res; 1999 Dec; 59(23):5878-81. PubMed ID: 10606227
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
[TBL] [Abstract][Full Text] [Related]
9. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
10. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
13. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
[TBL] [Abstract][Full Text] [Related]
14. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.
Park J; Chen L; Ratnashinge L; Sellers TA; Tanner JP; Lee JH; Dossett N; Lang N; Kadlubar FF; Ambrosone CB; Zachariah B; Heysek RV; Patterson S; Pow-Sang J
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1473-8. PubMed ID: 16896035
[TBL] [Abstract][Full Text] [Related]
15. Prostatic steroid 5 alpha-reductase, an androgen metabolic gene.
Reichardt JK
Mayo Clin Proc; 2000 Jan; 75 Suppl():S36-9. PubMed ID: 10959214
[TBL] [Abstract][Full Text] [Related]
16. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ
Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391
[TBL] [Abstract][Full Text] [Related]
17. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
Sobti RC; Onsory K; Al-Badran AI; Kaur P; Watanabe M; Krishan A; Mohan H
DNA Cell Biol; 2006 May; 25(5):287-94. PubMed ID: 16716118
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression.
Akalu A; Dlmajian DA; Highshaw RA; Nichols PW; Reichardt JK
J Urol; 1999 Apr; 161(4):1355-8. PubMed ID: 10081907
[TBL] [Abstract][Full Text] [Related]
19. A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.
Yang C; Hamajima N; Iwata H; Saito T; Matsuo K; Hirose K; Inoue M; Takezaki T; Tajima K
Breast Cancer Res; 2002; 4(4):R8. PubMed ID: 12100746
[TBL] [Abstract][Full Text] [Related]
20. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
Pearce CL; Van Den Berg DJ; Makridakis N; Reichardt JK; Ross RK; Pike MC; Kolonel LN; Henderson BE
Hum Mol Genet; 2008 Aug; 17(16):2456-61. PubMed ID: 18469342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
